Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G.
Atreya R, et al. Among authors: song a.
J Crohns Colitis. 2024 Nov 1:jjae164. doi: 10.1093/ecco-jcc/jjae164. Online ahead of print.
J Crohns Colitis. 2024.
PMID: 39485390